Provexis plc (LSE:PXS) — Market Cap & Net Worth
Market Cap & Net Worth: Provexis plc (PXS)
Provexis plc (LSE:PXS) has a market capitalization of $309.69K (GBX2.55 Billion) as of June 22, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30994 globally and #974 in its home market, demonstrating a 7.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Provexis plc's stock price GBX1.09 by its total outstanding shares 2345891239 (2.35 Billion). Review total liabilities of Provexis plc to assess the company's total debt and financial obligations.
Provexis plc Market Cap History: 2015 to 2026
Provexis plc's market capitalization history from 2015 to 2026. Data shows growth from $88.48K to $309.69K (8.94% CAGR).
Index Memberships
Provexis plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$937.70 Million | 0.03% | #262 of 722 |
Weight: Provexis plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Provexis plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Provexis plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.20x
Provexis plc's market cap is 0.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $138.43K | $227.62K | -$380.09K | 0.61x | N/A |
| 2018 | $71.36K | $235.80K | -$448.11K | 0.30x | N/A |
| 2019 | $186.95K | $322.19K | -$513.03K | 0.58x | N/A |
| 2020 | $228.34K | $347.94K | -$406.23K | 0.66x | N/A |
| 2021 | $232.62K | $505.33K | -$341.01K | 0.46x | N/A |
| 2022 | $206.93K | $426.17K | -$224.25K | 0.49x | N/A |
| 2023 | $185.53K | $598.08K | -$496.59K | 0.31x | N/A |
| 2023 | $185.53K | $389.92K | -$385.24K | 0.48x | N/A |
| 2024 | $192.66K | $801.96K | -$586.24K | 0.24x | N/A |
| 2025 | $256.88K | $1.29 Million | -$452.72K | 0.20x | N/A |
Competitor Companies of PXS by Market Capitalization
Companies near Provexis plc in the global market cap rankings as of June 22, 2026.
Key companies related to Provexis plc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Provexis plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Provexis plc's market cap moved from $88.48K to $ 309.69K, with a yearly change of 8.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX309.69K | +20.56% |
| 2025 | GBX256.88K | +33.33% |
| 2024 | GBX192.66K | +3.85% |
| 2023 | GBX185.53K | -10.34% |
| 2022 | GBX206.93K | -11.04% |
| 2021 | GBX232.62K | +1.88% |
| 2020 | GBX228.34K | +22.14% |
| 2019 | GBX186.95K | +162.00% |
| 2018 | GBX71.36K | -48.45% |
| 2017 | GBX138.43K | -42.94% |
| 2016 | GBX242.61K | +174.19% |
| 2015 | GBX88.48K | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Provexis plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $309.69K USD |
| MoneyControl | $309.69K USD |
| MarketWatch | $309.69K USD |
| marketcap.company | $309.69K USD |
| Reuters | $309.69K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and di… Read more